Skip to main content
Novartis
language-selector-globe
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
United States | English
    • About 
      Team meeting
      About

      Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story.

      • Novartis in the US 
      • Our US Leadership 
      • People and culture 
      • Products 
      • Therapeutic areas 
        • Oncology 
        • Immunology 
      • Inclusion and belonging 
      • Manufacturing 
      • Partnerships 
      • Contact us 
    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Patient assistance 
      • Diseases 
        • Chronic spontaneous urticaria (CSU) 
        • Hidradenitis suppurativa (HS) 
        • Prostate Cancer (PC) 
        • Paroxysmal Nocturnal Hemoglobinuria (PNH) 
        • Breast Cancer 
        • Sjögren's Disease 
      • Participating in clinical trials 
      • Adverse event reporting 
      • Patient resources 
      Patient smiling at doctor image
      Patients and caregivers

      Visit resources tailored for our patient communities and their caregivers, including information around patient assistance, disease information and related resources.

    • Healthcare professionals 
      • Novartis pipeline 
      • Novartis clinical trials 
      • Adverse event reporting 
      • External funding 
      • HCP resources 
      • Personalized and Precision Medicine 
      • Health Information Technology Resources 
      Two doctors examining X-ray
      Healthcare professionals

      Visit our resource hub for information around clinical trials, our products and innovation pipeline.

    • ESG 
      • Ethical behavior 
        • Code of ethics 
        • SpeakUp 
        • PhRMA Code on interactions with healthcare professionals 
        • Business principles 
      • Ethics, risk and compliance 
        • Compliance program 
        • State laws 
        • Payments to HCPs & HCOs 
        • Drug Supply Chain Security Act Information 
      • Corporate responsibility 
        • Novartis in Society Integrated Report 
        • Novartis US Foundation 
        • People and communities 
        • Beacon of hope 
      • Environmental sustainability 
      Family and friends party at home
      ESG

      Learn about our commitment to making a positive impact on society through innovative medicine access, sustainability, and governance.

    • News 
      • News archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting
      News

      Check out our media hub for the latest news, stories, and updates from across our business.

    • Careers 
      • Career search 
      • Early career 
      • Employee benefits 
      • Inclusion and belonging  
      Colleagues laughing
      Careers

      Check out what careers are available at Novartis in the U.S. and learn about our people and culture.

    Grandmother, mother and daughter smiling and laughing on a beach
    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Stories

Story Navigation
  • All Topics
  • Medicines
  • Discovery
  • Hope
  • Global Impact
  • Education & Awareness
icon
  • Reshema Kemps-Polanco
    Education and Awareness
    CareersFuture of HealthcareInnovationWomen in Science
    Aug 4, 2025

    Five Questions with Reshema Kemps-Polanco, Novartis US Chief Commercial Officer

    In this interview, Reshema Kemps-Polanco shares her top career tips, the mindset that drives her, and the quote she still lives by today.

    Education and Awareness
  • Large group photo of hundreds of Novartis San Diego research associates and scientists gathered in front of the GNF building in 2010
    Discovery
    Biomedical ResearchReimagine MedicineDrug DiscoveryInnovationScientific Research
    Aug 19, 2025

    Novartis in San Diego: A Quarter Century of R&D Innovation

    A look back at a legacy of biomedical research breakthroughs that trace their roots to our San Diego site. 
    Discovery
  • Portrait of Thierry Diagana, California Site Head for Novartis Biomedical Research, wearing black sweater and white collared shirt
    Discovery
    Biomedical ResearchDrug DiscoveryScientific ResearchInnovationReimagine Medicine
    Aug 19, 2025

    Designing for the Future: The Next Era of Biomedical Research in San Diego

    Thierry Diagana, California Sites Head at Novartis, shares the vision for a new research hub that will power future drug discovery.

    Discovery
  • Marice W right profile
    Education and Awareness
    Patient EducationPatient VoicesHeart DiseaseLiving With Disease
    Jul 30, 2025

    Maurice’s Story: How I Discovered I Had a Hidden Heart Disease Risk Factor

    Maurice W.*, a Medical Science Liaison at Novartis, was shocked to learn he had elevated Lp(a), an inherited risk factor for heart disease.1,2

    Education and Awareness
  • couple holding hands
    Education and Awareness
    Patient EducationPatient VoicesLiving With DiseaseDisease AwarenessDiseases
    Jul 10, 2025

    Tina’s Story: One Woman’s Burden of Living With Sjogren's Disease

    Education and Awareness
  • Novartis US Oncology Leader Speaking on Panel
    Hope
    CancerHeart DiseaseAccess to HealthcareSocial CommitmentReimagine Medicine
    Jun 17, 2025

    3 Innovative Ways We’re Reaching Patients, Beyond Our Medicines

    At Aspen Ideas Health, Novartis is leading conversations about how to address today’s most pressing healthcare concerns. Learn how we’re launching bold awareness campaigns and unique community partnerships—meeting patients where they are to drive change.

    Hope
  • Doctor consulting with older male patient and his wife about prostate cancer treatment options while reviewing information on computer screen in medical office
    Discovery / Cancer
    CancerEmerging TechnologyFuture of HealthcareOncologyReimagine Medicine
    Jun 5, 2025

    3 Ways We're Innovating Advanced Prostate Cancer Care

    Discovery
    Cancer
  • Katy, living with HS, smiling at camera
    Education and Awareness
    Living With DiseasePatient EducationPatient VoicesDisease EradicationDiseases
    May 29, 2025

    How Katy, a Patient Turned Advocate, Found Her Purpose

    Katy Shusta is helping to rewrite the narrative around hidradenitis suppurativa (HS) – a painful skin condition impacting as many as one in 100 people worldwide.1  

    Education and Awareness
  • A marching band marching down the street
    Education and Awareness
    Reimagine MedicineInnovationMedical InnovationsDigitalWorking at Novartis
    May 20, 2025

    Introducing the GARAGE by iLab: Behind the Scenes at Our New Innovation Hub

    Learn about the launch of our new state-of-the-art space, built to accelerate innovation from the inside out and provide new solutions for employees, partners and ultimately, our patients.

    Education and Awareness
  • time 100 health
    Hope
    Future of HealthcareCancerOncologyPatient Voices
    May 15, 2025

    Exploring the Future of Cancer Care at the Time100 Health Impact Dinner

    What does it mean to be diagnosed – or living with – cancer today? Novartis US President Victor Bultó offers insights into the changing oncology landscape.
    Hope
  • A smiling group of friends in a park.
    Discovery
    Future of HealthcareInnovationOncologyReimagine MedicineNext Generation Scientist
    May 16, 2025

    How We’re Reimagining Cancer Care for the Next Generation Patient

    Discovery
  • doctor and patient smiling
    Education and Awareness
    Cardiovascular DiseaseGenetic DiseaseHeart DiseaseDisease Awareness
    May 14, 2025

    Addressing Elevated Lipoprotein(a): The Importance of Testing At-Risk Patients

    Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD1.  Read on to learn more about patient populations at risk. 

    Education and Awareness

Pagination

  • ‹ Previous page
  • 1
  • 2
  • …
  • 4
  • › Next page

Novartis United States

Navigate Novartis
  • Patients & caregivers
  • Healthcare professionals
  • ESG
  • News
  • Careers
Media center
  • News archive
  • Statements
  • Stories
Our portfolio
  • Novartis clinical pipeline
  • Novartis product portfolio
Other Novartis US websites
  • Oncology HCP resources
  • Medical information
  • Global site
Footer Bottom
© 2025 Novartis Pharmaceuticals Corporation
  • Terms of use
  • Privacy policy
  • Consumer health privacy policy
  • Contacts
  • Cookie Settings
  • Site map
  • Web accessibility
Novartis Site Directory
This site is intended for US residents only